Inflammatory Markers and Atherogenic Coefficient: Early Markers of Metabolic Syndrome.
Hyperlipidemia
Inflammation
Metabolic Syndrome
Obesity
Triglyceride
Journal
International journal of endocrinology and metabolism
ISSN: 1726-9148
Titre abrégé: Int J Endocrinol Metab
Pays: Netherlands
ID NLM: 101235597
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
16
05
2022
revised:
11
07
2022
accepted:
09
08
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Considering the close link between metabolic syndrome (MetSyn) and cardiovascular diseases, considerable attention has been devoted to the identification of their shared underlying pathological mechanisms in recent decades. This study aimed to investigate the association between pro-inflammatory factors and newly-diagnosed MetSyn. This case-control study recruited obese and nonobese individuals who were newly diagnosed with MetSyn (cases, n = 84) and healthy individuals (controls, n = 83). The medical and sociodemographic data of the participants were collected on enrollment. Serum analysis was performed to ascertain the concentrations of tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), fasting blood sugar (FBS), total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and atherogenic coefficient (AC). Multiple regression analysis was carried out to explore the relationship between inflammatory markers and AC with MetSyn odds. The Pearson correlation test was also performed to investigate the correlations between metabolic and inflammatory parameters. Positive relationships were observed between the serum levels of TNF-α and CRP with the odds of MetSyn following controlling for confounders (adjusted odds ratio [AOR] = 1.32; 95% confidence interval [CI]: 1.01 - 1.72; AOR = 1.29; 95% CI: 1.18 - 1.41; respectively, P ≤ 0.03). Additionally, higher AC was accompanied by increased odds of MetSyn (AOR = 1.98; 95% CI: 1.31 - 2.98; P = 0.001). The Pearson correlation analysis also showed positive correlations between TNF-α levels and serum metabolic abnormalities, including elevated LDL-C, FBS, and AC and lowered HDL-C levels (P ≤ 0.02). The present results revealed that higher serum concentrations of pro-inflammatory and atherogenic indices, including CRP, TNF-α, and AC, might be associated with elevated odds of newly diagnosed MetSyn regardless of potential confounders, particularly body mass index. The obtained findings might be moderated by the positive correlations observed between serum TNF-α, as the chronic inflammatory state indicator, and impaired lipid and glycemic markers.
Sections du résumé
Background
UNASSIGNED
Considering the close link between metabolic syndrome (MetSyn) and cardiovascular diseases, considerable attention has been devoted to the identification of their shared underlying pathological mechanisms in recent decades.
Objectives
UNASSIGNED
This study aimed to investigate the association between pro-inflammatory factors and newly-diagnosed MetSyn.
Methods
UNASSIGNED
This case-control study recruited obese and nonobese individuals who were newly diagnosed with MetSyn (cases, n = 84) and healthy individuals (controls, n = 83). The medical and sociodemographic data of the participants were collected on enrollment. Serum analysis was performed to ascertain the concentrations of tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), fasting blood sugar (FBS), total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and atherogenic coefficient (AC). Multiple regression analysis was carried out to explore the relationship between inflammatory markers and AC with MetSyn odds. The Pearson correlation test was also performed to investigate the correlations between metabolic and inflammatory parameters.
Results
UNASSIGNED
Positive relationships were observed between the serum levels of TNF-α and CRP with the odds of MetSyn following controlling for confounders (adjusted odds ratio [AOR] = 1.32; 95% confidence interval [CI]: 1.01 - 1.72; AOR = 1.29; 95% CI: 1.18 - 1.41; respectively, P ≤ 0.03). Additionally, higher AC was accompanied by increased odds of MetSyn (AOR = 1.98; 95% CI: 1.31 - 2.98; P = 0.001). The Pearson correlation analysis also showed positive correlations between TNF-α levels and serum metabolic abnormalities, including elevated LDL-C, FBS, and AC and lowered HDL-C levels (P ≤ 0.02).
Conclusions
UNASSIGNED
The present results revealed that higher serum concentrations of pro-inflammatory and atherogenic indices, including CRP, TNF-α, and AC, might be associated with elevated odds of newly diagnosed MetSyn regardless of potential confounders, particularly body mass index. The obtained findings might be moderated by the positive correlations observed between serum TNF-α, as the chronic inflammatory state indicator, and impaired lipid and glycemic markers.
Identifiants
pubmed: 36714188
doi: 10.5812/ijem-127445
pmc: PMC9871968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e127445Informations de copyright
Copyright © 2022, International Journal of Endocrinology and Metabolism.
Déclaration de conflit d'intérêts
Conflict of Interests: The authors declare no conflict of interest associated with this manuscript.
Références
Rev Diabet Stud. 2019;15:60-70
pubmed: 31648293
Int J Mol Sci. 2022 Jan 12;23(2):
pubmed: 35054972
Clin Chim Acta. 2019 Sep;496:35-44
pubmed: 31229566
Int J Mol Sci. 2013 Jul 04;14(7):14008-23
pubmed: 23880853
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Complement Ther Med. 2020 Jun;51:102430
pubmed: 32507441
Adv Rheumatol. 2019 Nov 14;59(1):49
pubmed: 31727163
Exp Ther Med. 2020 Jul;20(1):121-128
pubmed: 32509004
Nutr Metab (Lond). 2022 Jan 6;19(1):2
pubmed: 34991636
Mediators Inflamm. 2010;2010:
pubmed: 20706689
Nutr Metab Cardiovasc Dis. 2004 Oct;14(5):228-32
pubmed: 15673055
Heart Lung Circ. 2022 May;31(5):e45-e71
pubmed: 35153150
Diabetol Metab Syndr. 2012 Jun 20;4(1):28
pubmed: 22716219
Arch Iran Med. 2010 Sep;13(5):426-8
pubmed: 20804311
Int J Mol Sci. 2018 Dec 11;19(12):
pubmed: 30544955
Diabetes. 1994 Nov;43(11):1271-8
pubmed: 7926300
Hipertens Riesgo Vasc. 2017 Apr - Jun;34(2):65-71
pubmed: 28039036
J Prev Med Public Health. 2008 Nov;41(6):413-8
pubmed: 19037171
Pak J Med Sci. 2021 May-Jun;37(3):700-705
pubmed: 34104151
J Clin Invest. 2019 Oct 1;129(10):3990-4000
pubmed: 31573548
J Clin Med. 2019 Oct 27;8(11):
pubmed: 31717832
Eur J Clin Invest. 2008 Jul;38(7):502-9
pubmed: 18489581
Int J Endocrinol Metab. 2018 Oct 21;16(4 Suppl):e84771
pubmed: 30584438
Mol Nutr Food Res. 2020 Feb;64(4):e1900797
pubmed: 31697015
Eur J Clin Invest. 2009 Jun;39(6):437-44
pubmed: 19397692
East Mediterr Health J. 2013 Mar;19(3):271-5
pubmed: 23879079